Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.46 USD | -3.95% | -5.19% | +37.74% |
Apr. 03 | North American Morning Briefing : Powell Awaited -2- | DJ |
Mar. 28 | SELLAS Life Sciences Group, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | 50.61M | Capitalization | 82.15M |
---|---|---|---|---|---|
Net income 2024 * | -40M | Net income 2025 * | -50M | EV / Sales 2024 * | - |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 1.62 x |
P/E ratio 2024 * |
-1.28
x | P/E ratio 2025 * |
-1.28
x | Employees | 16 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.5% |
Latest transcript on SELLAS Life Sciences Group, Inc.
1 day | -3.95% | ||
1 week | -5.19% | ||
Current month | +44.55% | ||
1 month | +44.55% | ||
3 months | +188.54% | ||
6 months | +56.05% | ||
Current year | +37.74% |
Managers | Title | Age | Since |
---|---|---|---|
Angelos Stergiou
FOU | Founder | 48 | 06-04-02 |
John Burns
DFI | Director of Finance/CFO | 39 | 13-04-30 |
Andrew Elnatan
LAW | General Counsel | - | 23-01-04 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 67 | 17-12-28 | |
David Scheinberg
BRD | Director/Board Member | 68 | 17-11-30 |
John Varian
BRD | Director/Board Member | 64 | 17-12-28 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-26 | 1.46 | -3.95% | 1,292,455 |
24-04-25 | 1.52 | -1.30% | 657,949 |
24-04-24 | 1.54 | -5.52% | 1,318,570 |
24-04-23 | 1.63 | +5.84% | 2,037,189 |
24-04-22 | 1.54 | 0.00% | 1,584,730 |
Delayed Quote Nasdaq, April 26, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+37.74% | 82.15M | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.73B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- SLS Stock